Sydnexis
PrivateLast Round
VC Round
Apr 15, 2025
Total Funding Raised
$50.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Sydnexis operates in Healthcare & Life Sciences and is based in Del Mar, California. Its latest recorded funding round was a VC Round in April 2025.
Sydnexis is a biopharmaceutical company that develops topical ophthalmic formulations, including its lead candidate SYD-101, aimed at slowing the progression of pediatric myopia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sydnexis Comparables
Compare Sydnexis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nevakar Inc. | 92% | |
| Eyenovia | 82% | |
| iVeena Delivery Systems | 79% |
For institutional investors. Book with your work email.
Sydnexis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 15, 2025 | ||||
| Series B | Aug 10, 2021 | ||||
| Series A | Oct 19, 2017 |
For institutional investors. Book with your work email.
Sydnexis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series A, Series B |
| RA Capital Management | Series A, Series B |
| SC Master Fund | Series B |
| Visionary Ventures | Series B |
| Medicxi | Series A, Series B |
| Bluestem Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 162% MoM.
- Mar 23, 2026
Presented Phase 3 STAR Trial data at the 2026 AAPOS Annual Meeting.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- sells_assets_toSep 22, 2026
Sydnexis sold Ligand Pharmaceuticals Incorporated an ascending tiered royalty interest in Ryjunea net sales in Europe, the Middle East, and Africa for a $23M upfront payment on Sep 22nd '26.
For institutional investors. Book with your work email.
Sydnexis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sydnexis's valuation, stock price, and market status.
Is Sydnexis a public or private company?
Sydnexis is a private company.
What is the current stock price of Sydnexis?
Sydnexis is a private company, so its shares have no public market price. Caplight tracks Sydnexis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sydnexis worth (valuation)?
Valuation information for Sydnexis is not publicly available.
Can I buy Sydnexis stock?
Sydnexis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sydnexis's last funding round?
Sydnexis's most recent funding round was VC Round on April 15, 2025.
Who are the main investors in Sydnexis?
Key investors in Sydnexis include SC Master Fund, Visionary Ventures, Bluestem Capital.
Will Sydnexis IPO soon?
No public IPO plans have been announced for Sydnexis.
How can I track Sydnexis secondary market activity?
Caplight tracks bids, offers, and trades in Sydnexis's shares on secondary markets.